SPR with Human LILRB1/CD85j/ILT2 Domain1&2?Protein 4360

ELISA with Human LILRB1/CD85j/ILT2 Domain1&2?Protein 4360

Binding assay with Human LILRB1/CD85j/ILT2 Domain1&2?Protein 4360

Human LILRB1/CD85j/ILT2 Domain1&2 Protein 4360

$210.00 – $700.00

Summary

Expression: HEK293
Functional: Yes (binding assay)
Amino Acid Range: Gly24-Gly221

SKU: 4360parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
accession	Q8NHL6
express system	HEK293
product tag	C-His
purity	> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
background	LILRB1, also known as CD85j and IL-T2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family. Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs.LILRB1 is a receptor for class I MHC antigens.
molecular weight	The protein has a predicted MW of 23.1 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Human LILRB1/CD85j/ILT2 Domain1&2 Protein 4360

protein

Size and concentration 100, 500µg and lyophilized
Form Lyophilized
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped at ambient temperature.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
LILRB1, also known as CD85j and IL-T2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family. Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs.LILRB1 is a receptor for class I MHC antigens.
Protein names Leukocyte immunoglobulin-like receptor subfamily B member 1 (LIR-1) (Leukocyte immunoglobulin-like receptor 1) (CD85 antigen-like family member J) (Immunoglobulin-like transcript 2) (ILT-2) (Monocyte/macrophage immunoglobulin-like receptor 7) (MIR-7) (CD antigen CD85j)
Gene names LILRB1,LILRB1 ILT2 LIR1 MIR7
Mass 9606Da
Function Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885). Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647). Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:19304799, PubMed:29262349). Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251).
Subellular location Cell membrane ; Single-pass type I membrane protein .; [Isoform 5]: Secreted .
Tissues Expressed in B cells, monocytes and various dendritic cell (DC) subsets including myeloid, plasmacytoid and tolerogenic DCs (at protein level) (PubMed:20448110, PubMed:24453251, PubMed:9285411, PubMed:9842885). Expressed in decidual macrophages (at protein level) (PubMed:19304799). Expressed in decidual NK cells (at protein level) (PubMed:29262349).
Structure Binds PTPN6 when phosphorylated (PubMed:9285411). Binds FCER1A and FCGR1A (PubMed:11907092, PubMed:9842885). Interacts with human cytomegalovirus/HHV-5 protein UL18 (PubMed:10591185). Interacts with peptide-bound HLA-G-B2M complex (PubMed:16455647). Interacts with peptide-bound HLA-F-B2M complex but not with peptide-free HLA-F open conformer. It does not probe the peptide sequence directly (PubMed:28636952).
Post-translational modification Phosphorylated on tyrosine residues. Dephosphorylated by PTPN6.
Domain Co
Target Relevance information above includes information from UniProt accession: Q8NHL6
The UniProt Consortium

Data

SPR with Human LILRB1/CD85j/ILT2 Domain1&2~-Protein

Human HLA-G Tetramer captured on CM5 Chip can bind Human LILRB1 Domain1&2, His Tag with an affinity constant of 1.9µM as determined in SPR assay (Biacore T200).

ELISA with Human LILRB1/CD85j/ILT2 Domain1&2~-Protein

Immobilized Human LILRB1 Domain1&2, His Tag at 1µg/ml (100µl/Well) on the plate. Dose response curve for Anti-LILRB1 Antibody, hFc Tag with the EC50 of 16.9ng/ml determined by ELISA (QC Test).

Binding assay with Human LILRB1/CD85j/ILT2 Domain1&2~-Protein

Serial dilutions of Anti-LILRB1 Antibody were added into Biotinylated Human HLA-G Complex Tetramer, His Tag : Human LILRB1 Domain1&2, His Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 34.6ng/ml.

HPLC of Human LILRB1/CD85j/ILT2 Domain1&2~-Protein

The purity of Human LILRB1 Domain1&2 is greater than 95% as determined by SEC-HPLC.

SDS-PAGE gel of Human LILRB1/CD85j/ILT2 Domain1&2~-Protein

Human LILRB1 Domain1&2 on Tris-Bis PAGE under reduced conditions. The purity is greater than 95%.

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.